Dr Reddy's Laboratories shuts all units after cyber attack on servers

Topics Dr Reddy's | Cyber Attack

Days after Hyderabad-based drug major Dr Reddy’s Laboratories (DRL) received approval from the Indian drug regulator to conduct phase-2 and 3 trials of the Russian Covid-19 vaccine candidate Sputnik V, the company had to shut its plants across the globe after a cyber attack on its servers. 

This is the second such attack on entities conducting vaccine research or trial. 

In July, Chinese hackers stole information from Spanish laboratories working on a Covid-19 vaccine, according to international news agencies. 

Though DRL’s Chief Information Officer Mukesh Rathi said the firm anticipated to restart services within 24 hours, the stock fell by 3 per cent on Thursday. However, it recovered to end the day’s trade at Rs 5,029.15 on the BSE, down 0.35 percent. 

Rathi said in a statement, “We are anticipating all services to be up within 24 hours and we do not foresee any major impact on our operations due to this incident”. 

Sources said the company is currently reviewing its IT network systems and trying to analyse how the breach occurred. 

It did not disclose details on what impact this shutdown would have on its manufacturing operations. 

The firm has 17 manufacturing plants and six research and development (R&D) centres in India. Globally, it has three R&D centres and six manufacturing units. 

The company draws nearly 80 per cent of its revenues from exports and has plants in Brazil, Russia, UK and the US. The breach is likely to have occurred in the wee hours of Thursday. 

Just last week, DRL received approval from the Drugs Controller General of India to conduct trials of Sputnik V. 

The vaccine candidate will first be tested on 100 volunteers before proceeding to a larger trial. 

After a meeting on October 16, the Subject Expert Committee on Covid-19 vaccines and drugs noted, “The firm should generate safety and immunogenicity data on 100 subjects in Phase II clinical trial and submit for evaluation before proceeding to Phase III clinical trial.”

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel